06:51 EST Viatris (VTRS) doesn’t see FDA warning impacting current 2024 financial guidance
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS:
- Viatris confirms receipt of warning letter, import alert for India facility
- Viatris announces publication of CARE study results
- Viatris Elects Directors and Amends Stock Plan at Meeting
- Viatris price target raised to $14 from $13 at Piper Sandler
- Viatris price target raised to $12 from $11 at Barclays